Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet?
- 15 October 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (20) , 4031-4034
- https://doi.org/10.1200/jco.2004.06.025
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2002
- Molecular characterisation of soft tissue tumours: a gene expression studyThe Lancet, 2002
- Clinical impact of molecular and cytogenetic findings in synovial sarcomaGenes, Chromosomes and Cancer, 2001
- Publication Bias: A Brief Review for CliniciansMayo Clinic Proceedings, 2000
- Association of SYT-SSX Fusion Types with Proliferative Activity and Prognosis in Synovial SarcomaLaboratory Investigation, 2000
- SYT–SSXGene Fusion as a Determinant of Morphology and Prognosis in Synovial SarcomaNew England Journal of Medicine, 1998
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994